Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches
10.1007/s13139-019-00586-x
- Author:
Makoto HOSONO
1
Author Information
1. Institute of Advanced Clinical Medicine and Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. hosono@med.kindai.ac.jp
- Publication Type:Review
- Keywords:
Radionuclide therapy;
Theranostics;
Radiopharmaceuticals
- MeSH:
Humans;
Radiation Protection;
Radioisotopes;
Radiopharmaceuticals;
Radiotherapy;
Theranostic Nanomedicine
- From:Nuclear Medicine and Molecular Imaging
2019;53(3):167-171
- CountryRepublic of Korea
- Language:English
-
Abstract:
Radionuclide therapy (RNT) stands on the delivery of radiation to tumors or non-tumor target organs using radiopharmaceuticals that are designed to have specific affinity to targets. RNT is recently called molecular radiotherapy (MRT) by some advocators in order to emphasize its characteristics as radiotherapy and the relevance of dosimetry-guided optimization of treatment. Moreover, RNT requires relevant radiation protection standards because it employs unsealed radionuclides and gives therapeutic radiation doses in humans. On the basis of these radiation protection standards, the development and use of radiopharmaceuticals for combined application through diagnostics and therapeutics lead to theranostic approaches that will enhance the efficacy and safety of treatment by implementing dosimetry-based individualization.
